Drugs / E1224
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03892213 | Oct → Dec 2014 | Chagas disease | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT03378661 | Nov 2016 → Jan 2018 | Chagas disease | Drugs for Neglected Diseases | Unknown | Met primary |
| Phase 2 | NCT01489228 | Jun 2011 → Aug 2012 | Chagas disease | Drugs for Neglected Diseases | Unknown | Missed primary |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2023-11-23 | Drugs for Neglected Diseases | Results World’s first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment dndi.org ↗
Results from the world’s first double-blind, randomized clinical trial to find a treatment for the fungal form of a chronic disabling disease called mycetoma have demonstrated that a new oral treatment, fosravuconazole, is safe, patient-friendly, and effective in treating the disease. |
| 2021-04-06 | Drugs for Neglected Diseases | Results Chagas disease: Shorter treatment just as effective as longer one, according to study in Bolivia published by The Lancet | DNDi dndi.org ↗
the study confirmed the new regimen, with fewer adverse effects, which has potential to be a new standard treatment. |
| 2019-03-13 | Drugs for Neglected Diseases | Results Study shows dramatically shorter treatment for Chagas disease could be just as effective, and significantly safer | DNDi dndi.org ↗
The results were presented for the first time today at the “XV Jornada sobre la Enfermedad de Chagas”, organised by the Barcelona Institute for Global Health (ISGlobal, a centre supported by “la Caixa”). |
| 2018-07-11 | Eisai Inc. | Regulatory ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG TO BE LAUNCHED IN JAPAN eisai.com ↗
Sato Pharmaceutical obtained marketing and manufacturing approval for NAILIN ® Capsules 100mg as an oral treatment for onychomycosis. |
| 2018-01-19 | Eisai Inc. | Regulatory ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG APPROVED IN JAPAN eisai.com ↗ |
| 2013-11-13 | Drugs for Neglected Diseases | Results Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy | DNDi dndi.org ↗
According to results of the first-ever Phase 2 clinical trial in Bolivia, conducted by the Drugs for Neglected Diseases initiative (DNDi), the experimental drug candidate E1224 showed good safety and was effective at clearing the parasite that causes Chagas disease, but had little to no sustained efficacy one year after treatment as a single medication. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-23 | Drugs for Neglected Diseases | World’s first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment dndi.org ↗ |
| 2021-04-06 | Drugs for Neglected Diseases | Chagas disease: Shorter treatment just as effective as longer one, according to study in Bolivia published by The Lancet | DNDi dndi.org ↗ |
| 2019-03-13 | Drugs for Neglected Diseases | Study shows dramatically shorter treatment for Chagas disease could be just as effective, and significantly safer | DNDi dndi.org ↗ |
| 2018-07-11 | Eisai Inc. | ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG TO BE LAUNCHED IN JAPAN eisai.com ↗ |
| 2018-01-19 | Eisai Inc. | ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG APPROVED IN JAPAN eisai.com ↗ |
| 2013-11-13 | Drugs for Neglected Diseases | Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy | DNDi dndi.org ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E1224 | “E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).” NCT03892213 ↗ |
| Route | Oral | “Patients were randomly assigned (1:1:1:1:1) to five oral treatment groups: high-dose E1224” PMID 29352704 ↗ Jan 2018 |